Organizing pneumonia in ALK+ non-small cell lung cancer treated with ceritinib: a case report
Abstract Introduction Anaplastic lymphoma kinase (ALK) inhibitors have been approved for non-small cell lung cancer (NSCLC) patients with ALK-rearrangement. Ceritinib, a clinically approved ALK inhibitor, is associated with some adverse reactions, including organizing pneumonia (OP). However, few ca...
Saved in:
| Main Authors: | Xiao Lin, Mengyao Xie, Dandan Ma, Dandan Zheng, Jingjing Liu, Jinyan Ye, Lehe Yang, Yao Lu |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer
2025-07-01
|
| Series: | Discover Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s12672-025-02904-6 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
CLINICAL EFFICACY OF TARGETED THERAPY TOWARDS METASTATIC LUNG CANCER CARRYING DISTINCT TYPES OF ALK REARRANGEMENTS
by: N. V. Mitiushkina, et al.
Published: (2020-09-01) -
Modern treatment of ALK-positive non-small cell lung cancer
by: D. A. Kharagezov, et al.
Published: (2022-06-01) -
Modification of Ceritinib Crystal Morphology via Spherical Crystallization
by: Iva Zokić, et al.
Published: (2024-11-01) -
Case Report: Ensartinib as a first-line treatment for SMARCA4-deficient and EML4-ALK non-small cell lung cancer
by: Yanqing Pan, et al.
Published: (2025-05-01) -
Case Report: Ocular metastasis from ALK-rearranged pulmonary adenocarcinoma presenting as a pseudo-syndrome of anterior uveitis
by: Cong Zhao, et al.
Published: (2025-08-01)